

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal633cxq

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * *
* *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 AUG 10 Time limit for inactive STN sessions doubles to 40
minutes
NEWS 3 AUG 18 COMPENDEX indexing changed for the Corporate Source
(CS) field
NEWS 4 AUG 24 ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced
NEWS 5 AUG 24 CA/CAplus enhanced with legal status information for
U.S. patents
NEWS 6 SEP 09 50 Millionth Unique Chemical Substance Recorded in
CAS REGISTRY
NEWS 7 SEP 11 WPIDS, WPINDEX, and WPIX now include Japanese FTERM
thesaurus
NEWS 8 OCT 21 Derwent World Patents Index Coverage of Indian and
Taiwanese Content Expanded
NEWS 9 OCT 21 Derwent World Patents Index enhanced with human
translated claims for Chinese Applications and
Utility Models
NEWS 10 OCT 27 Free display of legal status information in
CA/CAplus,
USPATFULL, and USPAT2 in the month of November.

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN customer
agreement. This agreement limits use to scientific research. Use
for software development or design, implementation of commercial
gateways, or use of CAS and STN data in the building of commercial
products is prohibited and may result in loss of user privileges

and other penalties.

* * * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 17:02:35 ON 04 NOV 2009

=> FIL BIOSIS CAPLUS EMBASE
COST IN U.S. DOLLARS
FULL ESTIMATED COST

SINCE FILE TOTAL
ENTRY SESSION
0.22 0.22

FILE 'BIOSIS' ENTERED AT 17:02:47 ON 04 NOV 2009
Copyright (c) 2009 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 17:02:47 ON 04 NOV 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 17:02:47 ON 04 NOV 2009
Copyright (c) 2009 Elsevier B.V. All rights reserved.

=> s CSNK or casein kinase
L1 12343 CSNK OR CASEIN KINASE

=> s l1 and RAC
L2 41 L1 AND RAC

=> s l2 and antisense
L3 7 L2 AND ANTISENSE

=> s l3 and PMO
L4 2 L3 AND PMO

=> dup rem 14
PROCESSING COMPLETED FOR L4
L5 2 DUP REM L4 (0 DUPLICATES REMOVED)

=> d bib abs 1-
YOU HAVE REQUESTED DATA FROM 2 ANSWERS - CONTINUE? Y/(N):Y

L5 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2004:471005 CAPLUS

DN 141:34681

TI Human modifier protein MRAC sequence homologs of the RAC pathway
and use in cancer diagnosis, therapy and drug screening

IN Kadyk, Lisa C.; Francis, George Ross; Bjerke, Lynn Margaret;
Lickteig, Kim

PA Exelixis, Inc., USA

SO PCT Int. Appl., 62 pp.

CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 2

| DATE | PATENT NO. | KIND | DATE | APPLICATION NO. |
|--|---|--|----------|-----------------|
| 20031124 | PI WO 2004048540 | A2 | 20040610 | WO 2003-US37547 |
| | WO 2004048540 | A3 | 20070830 | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA,
CH, CN,
GD, GE,
LC, LK,
NO, NZ,
TJ, TM, | CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI,
OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | |
| | RW: AZ, BY, EE, ES, SK, TR, TD, TG, | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, | | |
| 20031124 | CA 2506634 | AP, EA, EP, OA | A1 | CA 2003-2506634 |
| 20031124 | CA 2518381 | | A1 | CA 2003-2518381 |
| 20031124 | AU 2003295884 | | A1 | AU 2003-295884 |
| 20031124 | EP 1572973 | | A2 | EP 2003-787097 |
| 20031124 | R: MC, PT, SK | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, | | |
| 20031124 | JP 2006516097 | T | 20060622 | JP 2004-555681 |
| 20061031 | US 20070142271 | A1 | 20070621 | US 2006-535446 |
| PRAI US | 2002-428874P | P | 20021125 | |
| | WO 2003-US37547 | W | 20031124 | |
| ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT | | | | |
| AB The invention has designed a genetic screen to identify modifier genes of | | | | |
| RAC pathway that also affect cell migration in C. elegans, where | | | | |

various specific genes were silenced by RNA inhibition (RNAi) in a ced-10; mig-2 double mutant background. Casein kinase II and neurotropic tyrosine kinase receptor (MRAC) genes were identified as a modifier of the RAC pathway. Accordingly, vertebrate orthologs of these modifiers, and preferably the human orthologs, casein kinase (MRAC) genes are attractive drug targets for the treatment of pathologies associated with a defective RAC signaling pathway, such as cancer. The invention provides protein cDNA sequences of novel human orthologs of casein kinase (MRAC) genes. The invention also provides methods for utilizing these RAC pathway modifier genes and polypeptides to identify candidate therapeutic agents that can be used in the treatment of disorders associated with defective RAC pathway.

L5 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2004:471003 CAPLUS
DN 141:34679
TI Human casein kinase protein sequence homologs (CSNKs)
as modifiers of the RAC pathway and use in cancer diagnosis,
therapy and drug screening
IN Kadyk, Lisa C.; Francis, George Ross; Bjerke, Lynn Margaret
PA Exelixis, Inc., USA
SO PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2
PATENT NO. KIND DATE APPLICATION NO.
DATE -----

PI WO 2004048538 A2 20040610 WO 2003-US37545
20031124
WO 2004048538 A3 20071115
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA,
CH, CN,
GD, GE,
LC, LK,
NO, NZ,
TJ, TM,
RW: GH, GM, KE, LS, MW, MZ, SD, SZ, TZ, UG, ZM, ZW,
AZ, BY,

KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI,
SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
TD, TG, AP, EA, EP, OA
AU 2003295882 A1 20040618 AU 2003-295882
20031124 EP 1578941 A2 20050928 EP 2003-787095
20031124 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE,
MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU,
SK JP 2006516096 T 20060622 JP 2004-555679
20031124 US 20070141664 A1 20070621 US 2003-535445
20031124 PRAI US 2002-428874P P 20021125
WO 2003-US37545 W 20031124

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
AB The invention has designed a genetic screen to identify modifier
genes of

RAC pathway that also affect cell migration in *C. elegans*, where
various specific genes were silenced by RNA inhibition (RNAi) in
a *ced-10*,

mig-2 double mutant background. Casein kinase (CSNK) gene was identified as a modifier of the RAC pathway. Accordingly, vertebrate orthologs of these modifiers, and

preferably the human orthologs, casein kinase (CSNK) genes are attractive drug targets for the treatment of pathologies associated with a defective RAC signaling pathway, such

as cancer. The invention provides protein cDNA sequences of novel human orthologs of casein kinase (CSNK) genes.

The invention also provides methods for utilizing these RAC pathway modifier genes and polypeptides to identify candidate therapeutic agents that can be used in the treatment of disorders associated with

defective RAC pathway.

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

| | | |
|--|------------------|---------------|
| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
| FULL ESTIMATED COST | 22.75 | 22.97 |
| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE ENTRY | TOTAL SESSION |
| CA SUBSCRIBER PRICE
-1.64 | -1.64 | |

STN INTERNATIONAL LOGOFF AT 17:04:07 ON 04 NOV 2009